Bleeding and antidotes in new oral anticoagulants

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 2, 2013, Pages 191-202

  Majeed, Ammar ^a   Schulman, Sam ^a,b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

apixaban; bleeding reversal; dabigatran; edoxaban; rivaroxaban

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; DABIGATRAN; DESMOPRESSIN; EDOXABAN; PROTHROMBIN COMPLEX; PRT 4445; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; DRUG MEGADOSE; EMERGENCY SURGERY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 84882247210     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.07.001     Document Type: Review

References (60)

1. S.B. Olsson Executive steering committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
2. J. Stangier, K. Rathgen, and H. Stahle The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303
3. B.I. Eriksson, O.E. Dahl, and N. Rosencher Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
4. B. Eriksson, O. Dahl, and M. Huo Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) Thromb Haemost 105 2011 721 729
5. B.I. Eriksson, O.E. Dahl, and N. Rosencher Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
6. S. Schulman, C. Kearon, and A.K. Kakkar Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
7. S. Schulman, C. Kearon, and A.J. Kakkar Extended use of dabigatran, warfarin or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
8. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
9. B.I. Eriksson, L.C. Borris, and R.J. Friedman Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
10. M.R. Lassen, W. Ageno, and L.C. Borris Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
11. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
12. R. Bauersachs, S.D. Berkowitz, and B. Brenner Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
13. H.R. Buller, M.H. Prins, and A.W. Lensing Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 2012 1287 1297
14. M.R. Lassen, A. Gallus, and G.E. Raskob Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
15. M.R. Lassen, G.E. Raskob, and A. Gallus Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
16. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
17. T. Gomes, M.M. Mamdani, and A.M. Holbrook Rates of hemorrhage during warfarin therapy for atrial fibrillation CMAJ 185 2013 E121 E127
18. M.R. Southworth, M.E. Reichman, and E.F. Unger Dabigatran and postmarketing reports of bleeding N Engl J Med 368 2013 1272 1274
19. S. Schulman, R.J. Beyth, and C. Kearon Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 257S 298S
20. J.W. Eikelboom, L. Wallentin, and S.J. Connolly Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapY (RE-LY) trial Circulation 123 2011 2363 2372
21. A.L. Dans, S.J. Connolly, and L. Wallentin Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial Circulation 127 2013 634 640
22. M.L. Hansen, R. Sorensen, and M.T. Clausen Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch Intern Med 170 2010 1433 1441
23. G. Agnelli, H.R. Buller, and A. Cohen Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
24. J. Oldgren, M. Alings, and H. Darius Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial Ann Intern Med 155 2011 660 667
25. R.D. Lopes, S.M. Al-Khatib, and L. Wallentin Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial Lancet 380 2012 1749 1758
26. B.D. Fox, S.R. Kahn, and D. Langleben Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials BMJ 345 2012 e7498
27. G.Y. Lip, T.B. Larsen, and F. Skjoth Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J Am Coll Cardiol 60 2012 738 746
28. S. Schulman Is the network meta-analysis (NETMA) bringing us closer to the truth? insights from recent antithrombotic drug data Thromb Haemost 108 2012 872 875
29. F. Dentali, N. Riva, and M. Crowther Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
30. H. Shakur, I. Roberts, and R. Bautista Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial Lancet 376 2010 23 32
31. Y.K. Kagoma, M.A. Crowther, and J. Douketis Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials Thromb Res 123 2009 687 696
32. D.A. Henry, P.A. Carless, and A.J. Moxey Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Cochrane Database Syst Rev 2011 CD001886
33. D.F. O'Shaughnessy, C. Atterbury, and P. Bolton Maggs Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant Br J Haematol 126 2004 11 28
34. W.N. Erber, and D.J. Perry Plasma and plasma products in the treatment of massive haemorrhage Best Pract Res Clin Haematol 19 2006 97 112
35. A. Majeed, H.-G. Hwang, and M. Brueckmann Management and outcomes of major bleeding on dabigatran or warfarin Blood 120 2012 Abstr 19
36. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
37. S.H. Ibbotson, P.J. Grant, and R. Kerry The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro Thromb Haemost 65 1991 64 66
38. M. Elg, S. Carlsson, and D. Gustafsson Effects of activated prothrombin complex concentrate or recombinant factor VIIa on bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor Thromb Res 101 2001 145 157
39. K.H. Diehl, J. Romisch, and B. Hein Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models Haemostasis 25 1995 182 192
40. R. Marlu, E. Hodaj, and A. Paris Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers Thromb Haemost 108 2012 217 224
41. ®) in the correction of coagulation abnormalities induced by dabigatran Int J Lab Hematol 35 2013 222 224
42. W. Dager, and A. Roberts Reversing dabigatran with FEIBA in a patient with a transseptal perforation during cardiac ablation Crit Care Med 39 Suppl. 2011 243
43. H.J. Ehrlich, M.J. Henzl, and E.D. Gomperts Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events Haemophilia 8 2002 83 90
44. W. Zhou, S. Schwarting, and S. Illanes Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
45. I. Pragst, S.H. Zeitler, and B. Doerr Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model J Thromb Haemost 10 2012 1841 1848
46. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
47. A. Lillo-Le Louet, M. Wolf, and L. Soufir Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation Thromb Haemost 108 2012 583 585
48. M. Wolzt, M. Levi, and T.C. Sarich Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers Thromb Haemost 91 2004 1090 1096
49. S. Malherbe, B.C. Tsui, and K. Stobart Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII Anesthesiology 100 2004 443 445
50. T.E. Warkentin, P. Margetts, and S. Connolly Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding Blood 119 2012 2172 2174
51. J. Stangier, K. Rathgen, and H. Stahle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
52. M.R. Wanek, E.T. Horn, and S. Elapavaluru Safe use of hemodialysis for dabigatran removal before cardiac surgery Ann Pharmacother 46 2012 e21
53. M.K. Wychowski, and P.A. Kouides Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment Ann Pharmacother 46 2012 e10
54. F. Schiele, J. van Ryn, and K. Canada A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
55. D. Zhang, C.E. Frost, and K. He Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats Drug Metab Dispos 41 2013 906 915
56. W. Zhou, M. Zorn, and P. Nawroth Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban Stroke 44 2013 771 778
57. A. Godier, A. Miclot, and B. Le Bonniec Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 2012 94 102
58. A.C. Martin, B. Le Bonniec, and T. Lecompte Evaluation of recombinant activated factor vii, prothrombin complex concentrate and fibrinogen concentrate to reverse apixaban in a rabbit model J Am Coll Cardiol 59 2012 E573 [Abstr 904-8]
59. T. Fukuda, Y. Honda, and C. Kamisato Reversal of anticoagulant effects of edoxaban, an oral, direct factor xa inhibitor, with haemostatic agents Thromb Haemost 107 2012 253 259
60. A. Gruber, U.M. Marzec, and U. Buetehorn Reversal of the antihaemostatic effects of rivaroxaban by activated factor vii and activated prothrombin complex in primates Haematologica 94 Suppl. 2 2009 181 [Abstr 449]